MX2010002866A - Capas de mycoplasma gallisepticum atenuadas. - Google Patents

Capas de mycoplasma gallisepticum atenuadas.

Info

Publication number
MX2010002866A
MX2010002866A MX2010002866A MX2010002866A MX2010002866A MX 2010002866 A MX2010002866 A MX 2010002866A MX 2010002866 A MX2010002866 A MX 2010002866A MX 2010002866 A MX2010002866 A MX 2010002866A MX 2010002866 A MX2010002866 A MX 2010002866A
Authority
MX
Mexico
Prior art keywords
gallisepticum
attenuated
bacteria
live
reduced expression
Prior art date
Application number
MX2010002866A
Other languages
English (en)
Inventor
Mahesh Kumar
Muhammad Ayub Khan
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2010002866A publication Critical patent/MX2010002866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invenci?n proporciona bacterias Mycoplasma gallisepticum vivas atenuadas que exhiben una expresi?n reducida de una prote?na identificada como MGA_0621. En ciertas realizaciones, las bacterias atenuadas pueden exhibir adicionalmente una expresi?n reducida de una o m?s prote?nas seleccionadas del grupo constituido por piruvato deshidrogenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y prote?na ribos?mica L35 respecto a una bacteria M. gallisepticum de tipo silvestre. Se proporcionan tambi?n vacunas y procedimientos de vacunaci?n que implican el uso de las bacterias M. gallisepticum viva atenuadas y procedimientos para preparar bacterias M. galiisepticum vivas atenuadas. Se proporciona una cepa de M. gallisepticum viva atenuada ejemplar, designada MGx+47, que se mostr? por an?lisis prote?mico que exhib?a una expresi?n significativamente reducida de MGA_0621, y que se mostr? que era segura y eficaz cuando se administraba como vacuna contra infecci?n por M. gallisepticum en pollos.
MX2010002866A 2007-09-11 2008-09-10 Capas de mycoplasma gallisepticum atenuadas. MX2010002866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99344707P 2007-09-11 2007-09-11
PCT/US2008/010630 WO2009035644A1 (en) 2007-09-11 2008-09-10 Attenuated mycoplasma gallisepticum strains

Publications (1)

Publication Number Publication Date
MX2010002866A true MX2010002866A (es) 2010-04-01

Family

ID=40024216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002866A MX2010002866A (es) 2007-09-11 2008-09-10 Capas de mycoplasma gallisepticum atenuadas.

Country Status (22)

Country Link
US (4) US7935356B2 (es)
EP (2) EP2564868A1 (es)
JP (2) JP5451619B2 (es)
KR (2) KR20120014041A (es)
CN (1) CN101896195B (es)
AR (1) AR068418A1 (es)
AU (1) AU2008299913B2 (es)
BR (1) BRPI0817334A8 (es)
CA (1) CA2699410C (es)
CL (1) CL2008002675A1 (es)
CO (1) CO6260102A2 (es)
ES (1) ES2437593T3 (es)
HK (1) HK1145627A1 (es)
ME (1) ME00982B (es)
MX (1) MX2010002866A (es)
NZ (1) NZ583829A (es)
PL (1) PL2200640T3 (es)
RU (1) RU2441909C2 (es)
TW (1) TW200918666A (es)
UA (1) UA98506C2 (es)
WO (1) WO2009035644A1 (es)
ZA (1) ZA201001740B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
CA2799732A1 (en) * 2010-05-19 2011-11-24 Bioproperties Pty Ltd Methods relating to an attenuated mycoplasma
CN102168073B (zh) * 2010-11-30 2013-03-20 瑞普（保定）生物药业有限公司 一种提高疫苗生产中鸡毒支原体增殖能力的方法
CN103074246B (zh) * 2012-08-31 2015-09-02 南京天邦生物科技有限公司 一种低血清高效培养鸡毒支原体弱毒株培养基及其制备方法
CN107446859B (zh) * 2017-09-02 2020-12-18 河南省农业科学院畜牧兽医研究所 一株鸡毒支原体及其应用
CN112159479B (zh) * 2020-10-15 2022-03-22 福建农林大学 一种鸡毒支原体多抗原表位融合蛋白pMG-mEA及其应用
CN114045298B (zh) * 2021-09-09 2023-10-20 武汉科前生物股份有限公司 一种鸡滑液囊支原体亚单位疫苗及制备方法及应用
CN114940955B (zh) * 2022-05-10 2023-08-11 兆丰华生物科技(南京)有限公司 一种鸡毒支原体弱毒疫苗株及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566833B1 (fr) * 1984-06-27 1986-11-14 Inst Francais Du Petrole Methode et perfectionnement aux outils de forage comportant des passages d'eau permettant une grande efficacite du nettoyage du front de taille
EP0307976B1 (en) * 1987-09-18 1993-06-23 Akzo Nobel N.V. Mycoplasma vaccine
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US7599736B2 (en) * 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
EP1063297B1 (en) * 1999-06-22 2008-12-17 Korea Kumho Petrochemical Co. Ltd. Farnesyl pyrophosphate synthase (FPS) derived from seedlings of sunflower (Helianthus annus)
JP4723707B2 (ja) * 1999-12-22 2011-07-13 パナソニック電工株式会社 痩身器具
US6885888B2 (en) * 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US6922590B1 (en) * 2000-11-21 2005-07-26 Advanced Bionics Corporation Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US20020187162A1 (en) * 2001-04-21 2002-12-12 Geary Steven J. Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease
US6721603B2 (en) * 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US7551964B2 (en) * 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7239912B2 (en) * 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7076292B2 (en) * 2002-04-25 2006-07-11 Medtronic, Inc. Optical communication of neurostimulation-system information
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
US7155278B2 (en) * 2003-04-21 2006-12-26 Medtronic, Inc. Neurostimulation to treat effects of sleep apnea
UA87665C2 (ru) * 2003-07-25 2009-08-10 Берингер Ингельхайм Ветмедика, Инк. Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains

Also Published As

Publication number Publication date
PL2200640T3 (pl) 2014-02-28
EP2200640B1 (en) 2013-10-23
AU2008299913A1 (en) 2009-03-19
BRPI0817334A8 (pt) 2016-03-29
CA2699410A1 (en) 2009-03-19
CN101896195B (zh) 2013-04-03
CA2699410C (en) 2013-08-20
CL2008002675A1 (es) 2008-11-07
ME00982B (me) 2011-04-30
BRPI0817334A2 (pt) 2015-03-24
CO6260102A2 (es) 2011-03-22
KR101176717B1 (ko) 2012-09-03
US20110189099A1 (en) 2011-08-04
JP2014027950A (ja) 2014-02-13
AU2008299913B2 (en) 2014-05-08
US7935356B2 (en) 2011-05-03
US20090068232A1 (en) 2009-03-12
US20130302373A1 (en) 2013-11-14
US8298552B2 (en) 2012-10-30
ZA201001740B (en) 2014-03-26
RU2441909C2 (ru) 2012-02-10
RU2010108641A (ru) 2011-10-20
WO2009035644A1 (en) 2009-03-19
EP2564868A1 (en) 2013-03-06
ES2437593T3 (es) 2014-01-13
TW200918666A (en) 2009-05-01
UA98506C2 (en) 2012-05-25
KR20100061526A (ko) 2010-06-07
US20130022547A1 (en) 2013-01-24
CN101896195A (zh) 2010-11-24
JP5451619B2 (ja) 2014-03-26
NZ583829A (en) 2011-12-22
HK1145627A1 (en) 2011-04-29
AR068418A1 (es) 2009-11-18
KR20120014041A (ko) 2012-02-15
EP2200640A1 (en) 2010-06-30
JP2010538646A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
MX2010002866A (es) Capas de mycoplasma gallisepticum atenuadas.
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
WO2010060051A3 (en) Systems biology approach predicts the immunogenicity of vaccines
MX342443B (es) Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.
MX2010000864A (es) Vacuna de celulas enteras estafilococcicas inactivadas.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
WO2009058833A3 (en) Mycoplasma bovis vaccine
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
GB2453475A (en) Live vaccine strains of francisella
MX2012003827A (es) Toxina rtx citolitica de gallibacterium anatis.
GB2458057A (en) Francisella strain for live vaccine
NZ589981A (en) Cattle vaccines comprising a disrupted M. bovis bacterium
WO2012009774A3 (pt) Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
GB2515222A (en) Use of flagellin as a vaccine
ATE454164T1 (de) Francisella-stamm für lebenden impfstoff
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
WO2008058116A3 (en) Tbpb proteins in attenuated oral live vaccines
PH12014501688A1 (en) Influenza c virus and vaccine
MX2021015155A (es) Polisacaridos de ramnosa.
Kharb et al. Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida B: 2 in mice model
Okay Development of recombinant vaccines composed of plpe and omph from Pasteurella multocida A: 3
TH103204B (th) สายพันธุ์ไมโคพลาสมาแกลลิเซพทิคัมที่ถูกทำให้อ่อนกำลังลง
TH103204A (th) สายพันธุ์ไมโคพลาสมาแกลลิเซพทิคัมที่ถูกทำให้อ่อนกำลังลง
Khafagy et al. Identity of Salmonella Enterica Serovar Enteritidis, Typhimurium and Kentucky Local Strains Used In Preparation of Polyvalent Inactivated Salmonella Vaccine in Chickens in Egypt.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status